CROSSJECT SA
DIJON, BOURGOGNE-FRANCHE-COMTE 21000
$115.44M
Total Contract Value
5 awards
First Award
Jun 9, 2022
Last Award
Sep 16, 2025
Business Size
other than small
CAGE Code
FBEF0
Top Industries (NAICS)
| NAICS Code | Obligations | Awards |
|---|---|---|
| 541714 | $104.15M | 4 |
Contract Awards
2 awards found
75A50122C00031
Department of Health and Human Services
$11.29M
Sep 16, 2025
SUPPLEMENTAL FUNDING FOR CLIN 001 AND REVISED THE STATEMENT OF WORK.
NAICS: 541714 - RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)FY2025
75A50122C00031
Department of Health and Human Services
$92.86M
Jun 9, 2022
ADVANCED RESEARCH AND DEVELOPMENT AND DELIVERY OF ADULT AND PEDIATRIC MIDAZOLAM AUTOINJECTORS THAT HAVE RECEIVED EMERGENCY USE AUTHORIZATION (EUA) OR FDA APPROVAL FOR THE TREATMENT OF STATUS EPILEPTICUS SEIZURES IN ADULT AND PEDIATRIC POPULATIONS (2+
NAICS: 541714 - RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)FY2022
Business Details
- UEI
- NLXZHCL3NLL3
- CAGE Code
- FBEF0
- Address
- ZAC PARC MARZEN SULLY
6 RUE PAULINE KERGOMARD
DIJON, 21000
Parent Company
CROSSJECT SA
Data Source
This profile is based on federal contract award data from USAspending.gov.
View on USAspending.gov